-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Innate Pharma, Lowers Price Target to $11

Benzinga·04/24/2025 11:08:24
Listen to the news
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and lowers the price target from $11.5 to $11.